Gut Microbiota Dysbiosis Remodels the Multi-Tissue Transcriptional Landscape of the Host

The trillions of bacteria living in our gut do far more than aid digestion — they appear to shape how genes are switched on and off in organs throughout the body. This mouse study systematically mapped those effects by first depleting the gut microbiota with antibiotics and then restoring it, while measuring gene activity across six tissues: the colon, small intestine (jejunum), liver, heart, lung, and kidney. The researchers identified 7,365 genes whose activity is meaningfully influenced by the presence or absence of gut bacteria, with the colon showing the strongest response. Strikingly, the microbiota's influence was tissue-specific: it tuned immune-related genes in the gut and lung, and metabolism-related genes in the liver. The team also found that several of these microbiota-sensitive genes are linked to patient survival in human cancers, including liver, lung, and kidney cancers — hinting that microbiota-driven gene regulation may have clinical relevance beyond the gut. A newly highlighted mechanism involves a molecule called Noct, whose transcription in colon cells is suppressed by gut bacteria and appears to modulate communication along the gut-liver axis. These findings offer one of the most comprehensive 'atlases' to date of how gut bacteria remotely govern gene expression across multiple organs simultaneously.

• Whole-transcriptome sequencing across six tissues identified 7,365 effector genes whose expression was significantly altered by gut microbiota presence versus depletion, with the colon exhibiting the most pronounced transcriptional remodeling.
• Tissue-specific functional enrichment showed immunity-related pathways were predominantly regulated in the gut and lung, while metabolic pathways were most affected in the liver, demonstrating organ-specific rather than uniform systemic responses.
• LASSO regression-refined key effector genes showed significant associations with patient survival in corresponding human cancers — specifically liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), and kidney renal clear cell carcinoma (KIRC) — suggesting translational relevance of microbiota-regulated gene programs.
• Gut microbiota broadly remodeled competing endogenous RNA (ceRNA) networks across tissues, implicating a post-transcriptional regulatory layer in addition to direct transcriptional effects.
• Single-cell data analysis identified colonic enterocytes and hepatic cholangiocytes as the primary cell types mediating gut-liver axis communication, with gut bacteria repressing transcription of Noct in enterocytes; Noct expression was significantly negatively correlated with gut-liver axis interaction strength.

This is a controlled animal study using mice subjected to gut microbiota depletion (method not fully detailed in abstract, likely antibiotic cocktail) followed by microbiota restoration, with six tissues sampled per condition: colon, jejunum, liver, heart, lung, and kidney. Whole-transcriptome (RNA) sequencing was performed on all tissues, and effector genes were identified using a linear mixed-effects model. LASSO regression was applied for further gene prioritization, and ceRNA network analysis and single-cell RNA-seq data integration were used to explore regulatory mechanisms and cell-type-specific interactions. Human cancer survival data were queried to assess the clinical relevance of identified effector genes.

As an animal study in mice, direct translation to human physiology is uncertain — the specific microbiota composition, depletion method, and restoration dynamics may not replicate the complexity of human dysbiosis or disease states. The study identifies correlative transcriptional associations with human cancer survival rather than establishing causal relationships, so whether microbiota-regulated gene expression actively drives tumor outcomes remains unresolved. The abstract does not specify sample sizes per group or the exact antibiotic regimen, limiting full methodological appraisal. Future experiments should validate key effector genes (particularly Noct) in human intestinal organoids or germ-free humanized mouse models and use longitudinal designs to capture the temporal dynamics of transcriptional remodeling during dysbiosis.

This study extends [§87], which examines how gut microbiota regulates systemic inflammatory responses via macrophage-targeting mechanisms, by demonstrating that dysbiosis-driven gene remodeling spans immune, metabolic, and post-transcriptional layers across at least six distinct tissues simultaneously. It parallels [§88], which uses large-scale metagenomics to link enterotype-specific microbiota features to immune checkpoint inhibitor response, in that both works implicate microbiota composition as a determinant of host immune gene programs with direct oncological relevance — though the present study approaches this through controlled transcriptomic perturbation rather than observational clinical cohorts. The gut-liver axis findings reinforce themes explored in [§127], where microbiota changes mediate hepatoprotective effects, and align with [§101]'s focus on microbial-bile acid crosstalk as a driver of metabolic liver pathology. Taken together, these articles collectively build a picture of the gut microbiome as a systemic transcriptional regulator, with the current study providing one of the most tissue-breadth-comprehensive mechanistic frameworks to date.

• Gut Microbiota Regulates Systemic Inflammatory Response and Compensatory Anti-Inflammatory Response Syndromes by Targeting PF4+ Macrophages in Acute Pancreatitis
  Both examine how gut microbiota dysbiosis drives systemic inflammatory gene programs across multiple organs, making direct mechanistic comparison valuable — Article 87 focuses on macrophage-mediated immune signaling while this study maps the full multi-tissue transcriptome.
• Enterotype-specific microbial biomarkers of immune checkpoint inhibitor response revealed by large-scale integrated metagenomic analysis
  Both link microbiota composition to cancer-relevant immune gene expression, but Article 88 uses large human clinical cohorts and immune checkpoint inhibitor outcomes, providing a translational counterpart to this study's controlled mouse transcriptomics.
• The human microbiome at translational crossroads: an ecological and causal perspective
  Article 100 offers an ecological and causal framework for interpreting human microbiome studies, which is directly useful context for evaluating the causal inference limitations of this depletion-restoration mouse model.
• A single-strain dropout screen reveals mechanistic links between microbial ecology and metabolism
  Article 24's single-strain dropout approach in a community ecology model complements this study's whole-microbiota depletion strategy, together illuminating how individual versus community-level microbiota changes drive mechanistic host responses.
• Integrated gut microbiota and metabolome signatures revealed by deep metagenomic sequencing in post-stroke cognitive impairment with type 2 diabetes
  Article 86 integrates metagenomics and metabolomics to link gut microbiota signatures to systemic organ outcomes (cognitive impairment post-stroke), paralleling this study's multi-tissue transcriptomic approach and offering a human-data complement to the mouse findings.